why choose us

Clinical Trials Search

Showing 8,650 of 132,963 result(s)
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Status: COMPLETED

Condition: Hypothalamic Obesity

Interventions: Oral daily administration

Date: 2023-09-14

Adaptation and Feasibility of the Community-Based Anxiety Program Tailored for Autism (CAPTA)

Status: COMPLETED

Condition: Anxiety

Interventions: Participants will receive cognitive behavioral therapy with elements of exposure in order to target anxious behaviors.

Date: 2023-09-14

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Status: COMPLETED

Condition: Hidradenitis Suppurativa

Interventions: DRUG: Eltrekibart - Administered SC
DRUG: Placebo - Administered SC

Date: 2023-09-14

Decremental Esophageal Catheter Filling Volume Titration For Transpulmonary Pressure Measurement

Status: COMPLETED

Condition: Pediatric Acute Respiratory Distress Syndrome (PARDS)
Acute Respiratory Failure
Acute Resp

Interventions: OTHER: Fast method - Fast decremental catheter volume titration will be applied and optimal filling volume will be determined according to the measure

Date: 2023-09-14

Combination of Buffered Anesthetic to Treat Mandibular Molars

Status: Completed

Condition: Symptomatic Irreversible Pulpitis

Interventions: Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic

Date: 2023-09-14

Community Health Advocates for Motivating PAP Use in Our Neighborhoods.

Status: NOT_YET_RECRUITING

Condition: Obstructive Sleep Apnea

Interventions: Motivational Enhancement Therapy (MET) is based on the principles of motivational interviewing and is designed to promote self-efficacy and maximize b

Date: 2023-09-14

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Status: Completed

Condition: Hidradenitis Suppurativa

Interventions: Administered SC

Date: 2023-09-14

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed;Refractory Mantle Cell Lymphoma

Status: Completed

Condition: Lymphoma

Interventions: Participants will receive two 1000 mg pretreatments of intravenous (IV) obinutuzumab from Cycle 1 Day 1

Date: 2023-09-14

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Status: Completed

Condition: Episodic Migraine

Interventions: Dose "A" U ;Injection (U;I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.

Date: 2023-09-14

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Status: Completed

Condition: Chronic Migraine

Interventions: Dose "A" Unit;Injection (U;I), Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.

Date: 2023-09-14